Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models
Surgery followed by a chemotherapy agent is the first-line treatment for breast cancer patients.Nevertheless, new DR. FORMULATED PROBIOTICS ONCE DAILY ULT targets are required for women with triple-negative breast cancer (TNBC) in order to improve the treatment of this aggressive cancer subtype.Multiple pro-inflammatory molecules including lipid-ba